Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ ...
On April 23, Tata Communications stock climbed 5.6% to ₹1,609 after a solid Q4 report showing 11.5% YoY data revenue growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results